RxDoctor Payments Data

Chao Li, MD

Ophthalmology · Charlotte, NCNPI 1154819290

Payments from drug & device makers

$5,411in general payments, 2019–2025

Across 84 payments — averaging $64.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$3K
  • AbbVie$416
  • Sight Sciences, Inc.$354
  • Bausch & Lomb Americas Inc.$277
  • Johnson & Johnson Surgical Vision, Inc.$168
  • Harrow Eye, LLC$153
  • plus $646 from 14 others

What the payments were for

  • Travel & lodging$1,03619%
  • Food & beverage$4,37481%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,411 in reported general payments places this provider in the 75th percentile of 588 ophthalmology providers in North Carolina.

See all ophthalmology providers in North Carolina

Medicare billing

Part B allowed, 2024
$288,061
Medicare patients
977
Services billed
2,206

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine60$46,694
XiidraLifitegrast49$38,372
MieboPerfluorohexyloctane/Pf11$8,320
Cyclosporine22$4,591
Latanoprost343$4,403
Prednisolone Acetate101$2,771
Travoprost12$2,246
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat107$1,578
Brimonidine Tartrate61$1,290
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha80$809
Fluorometholone13$764
ValacyclovirValacyclovir Hcl19$519
Doxycycline Hyclate37$370
Dorzolamide Hcl14$306
Timolol Maleate76$271

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$416$46,69460 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo$277$46,69260 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 588 ophthalmology providers in North Carolina.

Other ophthalmology in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →